Core Viewpoint - The company, Dachen Biochemical Technology (00809), is actively engaging in strategic partnerships to enhance its capabilities in synthetic biology, particularly in the context of the Changchun Economic and Technological Development Zone initiative [1][2]. Group 1: Strategic Partnerships - Dachen Biochemical Technology's subsidiary, Changchun Hongcheng Biochemical Materials Technology Development Co., Ltd., has entered into a strategic cooperation framework agreement with Hefei Hechen Biotechnology Co., Ltd. to leverage their respective strengths in synthetic biology [2]. - The collaboration aims to focus on the industrial application of synthetic biology in the amino acid sector, combining Dachen's expertise in process optimization and cost control with Hefei Hechen's strengths in gene design and metabolic pathway optimization [2]. Group 2: Industry Development Initiatives - The Changchun Economic and Technological Development Zone is establishing a synthetic biology industry innovation development pilot area, with the goal of promoting high-quality industrial development in Northeast China [1]. - A key aspect of the initiative includes the signing of the Changxing Oasis Sub-Fund, which has been established with a capital of RMB 50 million, focusing on applications of synthetic biology in biomanufacturing, agricultural technology, and green energy [1]. Group 3: Research and Development Facilities - The strategic cooperation will utilize the research center and pilot facilities located at the company's Xinglongshan production base, which includes approximately 10,000 square meters of factory space and four research and development centers [2]. - The pilot platform's inauguration during the conference signifies a crucial step in bridging the gap between technological achievements and industrial application, particularly in biobased chemicals and medical materials [2]. Group 4: Current Operations Status - As of the announcement date, the company's Xinglongshan production base remains suspended from operations [3].

Group 1 - The core viewpoint of the news is that Dachen Biochemical Technology (00809.HK) has entered into a strategic cooperation framework agreement with Hefei Hechen Biotechnology Co., focusing on the development of synthetic biology applications in the amino acid sector [1][2] - The strategic cooperation aims to leverage the strengths of both parties in synthetic biology, combining Dachen's experience in technology scaling, process optimization, and cost control with Hefei Hechen's expertise in gene design and metabolic pathway optimization [1][2] - A pilot platform for synthetic biology will be established at Dachen's Xinglongshan production base, which includes approximately 10,000 square meters of research and development facilities, supporting the industrialization of bio-based chemicals and medical materials [2] Group 2 - The unveiling of the pilot platform during the conference signifies a crucial step in bridging the gap between technological achievements and industrial application, facilitating breakthroughs in the bio-based chemical and medical materials sectors [2] - Hefei Hechen is focused on integrating synthetic biology with advanced delivery technologies, developing bio-based chemicals, specialty amino acids, and high-value active ingredients, as well as offering solutions for beauty products and functional food applications [2]